1985
DOI: 10.1111/j.1651-2227.1985.tb10973.x
|View full text |Cite
|
Sign up to set email alerts
|

Intrathecal Administration of Human Leukocyte Interferon to a Patient with Subacute Sclerosing Panencephalitis

Abstract: An eight-year-old boy with subacute sclerosing panencephalitis was treated with human leukocyte interferon (HuIFN-alpha) by intravenous and intrathecal injections. We observed some remarkable improvements in his clinical course.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

1987
1987
1996
1996

Publication Types

Select...
4
2

Relationship

0
6

Authors

Journals

citations
Cited by 14 publications
(1 citation statement)
references
References 4 publications
0
1
0
Order By: Relevance
“…This is in spite of the observations that IFN may be involved in the establishment of persistent infections by measles virus in vitro (24,43) and that it can serve as a marker for persistent CNS infection by canine distemper virus in dogs (49). Furthermore, in trials of intrathecal or intraventricular IFN as a treatment for SSPE (6,7,9,22,(39)(40)(41)(42)47), clinical improvement has been observed in 9 of 19 (47%) patients, which is in contrast with the approximately 10% of patients with SSPE that show spontaneous stabilization or improvement (44,45). Furthermore, by combining the results reported with some of these trials with those reported in other studies (6,7,9,22,29), it can be seen that of 20 patients with SSPE whose cerebrospinal fluid was assayed for IFN by bioassay before treatment with IFN, only 4 (20%) had detectable levels.…”
Section: Discussionmentioning
confidence: 99%
“…This is in spite of the observations that IFN may be involved in the establishment of persistent infections by measles virus in vitro (24,43) and that it can serve as a marker for persistent CNS infection by canine distemper virus in dogs (49). Furthermore, in trials of intrathecal or intraventricular IFN as a treatment for SSPE (6,7,9,22,(39)(40)(41)(42)47), clinical improvement has been observed in 9 of 19 (47%) patients, which is in contrast with the approximately 10% of patients with SSPE that show spontaneous stabilization or improvement (44,45). Furthermore, by combining the results reported with some of these trials with those reported in other studies (6,7,9,22,29), it can be seen that of 20 patients with SSPE whose cerebrospinal fluid was assayed for IFN by bioassay before treatment with IFN, only 4 (20%) had detectable levels.…”
Section: Discussionmentioning
confidence: 99%